• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AstraZeneca, Karolinska Institutet collaborate on molecular imaging research

AstraZeneca, Karolinska Institutet collaborate on molecular imaging research

June 21, 2012
CenterWatch Staff

Global biopharmaceutical company AstraZeneca and Karolinska Institutet, a medical university in Sweden, have entered into a three year collaborative research agreement that will apply state-of-the-art molecular imaging technologies to generate novel diagnostic imaging tools and further the development of AstraZeneca’s neuroscience R&D pipeline.

AstraZeneca and Karolinska Insitutet have collaborated since 2006 in the field of positron emission tomography (PET), a modern imaging technique allowing for non-invasive examination of the human brain. This joint venture and application of complementary capabilities has led to the invention of numerous novel PET ligands, as well as aided in the development of a number of drug development programs. Continued collaboration between AstraZeneca and the university is expected to deliver new imaging tools for the diagnosis of patients primarily with severe neurological illnesses as well as in pain control. In addition, the alliance will facilitate the development of drugs for disorders such as chronic pain, Alzheimer’s and Parkinson’s disease, where there is an urgent need for new treatments.

AstraZeneca scientists will supply the technologies and skills required to synthesize and develop new imaging molecules, while the PET Centre at Karolinska Institutet will provide radiochemistry for labeling of the imaging molecules and the PET-studies required to support and facilitate AstraZeneca projects.

“Demonstrating robust target engagement is one of the critical success criteria for transitioning molecules through early research and development. Working with our colleagues from Karolinska Institutet will help us identify and develop new PET ligands and accelerate our efforts to deliver novel medicines to patients,” said Menelas Pangalos, executive vice president of innovative medicines, AstraZeneca.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing